Literature DB >> 2665851

The in vivo effects of recombinant human interleukin-3: demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhuman primates.

P Mayer1, P Valent, G Schmidt, E Liehl, P Bettelheim.   

Abstract

Recently human interleukin-3 (IL-3) produced by molecular cloning was characterized as a growth factor for basophils and eosinophils in human bone marrow cultures. Since we found a similar activity of the human factor on simian bone marrow cells, we investigated the in vivo effects of recombinant human (rh) IL-3 in healthy rhesus monkeys (n = 10). rh IL-3 was administered subcutaneously (SC) to monkeys at different doses (11, 33, and 100 micrograms/kg/d) for 14 days followed by subsequent rh GM-CSF administration (5.5 micrograms/kg/d SC) for another two weeks. During the second week of rh IL-3 administration monkeys responded with a twofold to threefold increase of WBCs caused by a dose-dependent elevation of basophils (up to 40% of WBCs) and eosinophils. rh IL-3 also induced a dose-dependent increase of histamine (up to 700-fold above normal values) in monkey blood cells. Administration of rh GM-CSF to rh IL-3 pretreated monkeys resulted in a twofold enhanced increase in WBCs (due mainly to eosinophils and neutrophils) compared with animals treated with rh GM-CSF alone. Simultaneous administration of both cytokines (100 micrograms/kg rh IL-3 + 5.5 micrograms/kg rh GM-CSF SC) to two separate monkeys for 14 days induced a WBC elevation similar to that observed in monkeys treated with rh GM-CSF alone. In conclusion, our results indicate that rh IL-3 is a differentiation factor for blood basophils and primes the hematopoietic system for subsequent rh GM-CSF actions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2665851

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.

Authors:  P Valent; K Sotlar; K Blatt; K Hartmann; A Reiter; I Sadovnik; W R Sperr; P Bettelheim; C Akin; K Bauer; T I George; E Hadzijusufovic; D Wolf; J Gotlib; F-X Mahon; D D Metcalfe; H-P Horny; M Arock
Journal:  Leukemia       Date:  2017-01-16       Impact factor: 11.528

Review 2.  Cytokine-induced human basophil/mast cell growth and differentiation in vitro.

Authors:  J A Denburg
Journal:  Springer Semin Immunopathol       Date:  1990

3.  Acute basophilic leukemia lacking basophil-specific antigens: the importance of cytokine receptor expression in differential diagnosis.

Authors:  Akihiko Yokohama; Norifumi Tsukamoto; Nahoko Hatsumi; Miwa Suto; Tohru Akiba; Hideki Uchiumi; Tadashi Maehara; Takafumi Matsushima; Masamitsu Karasawa; Hirokazu Murakami; Shougo Shinonome; Hirohisa Saito; Yoshihisa Nojima
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

4.  Cytokine-dependent long-term culture of highly enriched precursors of hematopoietic progenitor cells from human bone marrow.

Authors:  J Brandt; E F Srour; K van Besien; R A Briddell; R Hoffman
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

5.  The growth capacity of hematopoietic progenitor cells in severe neutropenia induced by famotidine.

Authors:  T Liersch; J H Beyer; G Krieger; K Vehmeyer
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

Review 6.  Prediction of the role of granulocyte-macrophage colony-stimulating factor in animals and man from in vitro results.

Authors:  E Liehl; J Hildebrandt; C Lam; P Mayer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

Review 7.  Why clinicians should be interested in interleukin-3.

Authors:  P Valent; K Geissler; C Sillaber; K Lechner; P Bettelheim
Journal:  Blut       Date:  1990-12

8.  Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates.

Authors:  A P Gillio; C Gasparetto; J Laver; M Abboud; M A Bonilla; M B Garnick; R J O'Reilly
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

9.  Acute side effects of homologous interleukin-3 in rhesus monkeys.

Authors:  F C van Gils; A H Mulder; C van den Bos; H Burger; R W van Leen; G Wagemaker
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

10.  In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity.

Authors:  N Van der Lely; T De Witte; J Wessels; R Raymakers; P Muus; F Preijers
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.